Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAL0140 in Uncontrolled Hypertension
NCT07654140Phase 2Recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAL0140 in hypertension (HTN) and resistant hypertension (RH) (4 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Mean seated systolic blood pressure at 12 weeks. Started Dec 2025; status: recruiting.
02
Drugs
SAL0140
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07654140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654140.